Address:
1-6-1 Okubo, Kita-ku, Kumamoto, 860-8568, Japan
Phone Number:
+81-96-344-2755
Fax Number:
+81-96-300-3395
Company Contact Email:
global-strategy@kmbiologics.com
Website:
https://www.kmbiologics.com/en/
Employees:
2,029 (June 2023)
Capital:
USD 71.4M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)
Revenue:
USD 306M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)
Main Clients:
Meiji Seika Pharma
Introduction of your company & business:
KM Biologics supplies first-rate biological products and services with sophisticated skills and knowledge based on over 70 years of combined experience. Our main businesses include the following:
Human Vaccines
Blood Plasma Products
Veterinary Vaccines
Newborn Screening
Mission/Vision:
Our responsibility as disease prevention and treatment professionals is to continuously push the limits of life sciences to shape a healthy future for people around the world.
History:
1945: Establishment of our predecessor, Kaketsuken
1946: Vaccine production for smallpox and cholera, a combined vaccine against typhus and paratyphoid, and a tetanus antitoxin started.
1964: Approval of DPT vaccine.
1988: Launch of Bimmugen – the first Japanese recombinant Hepatitis B vaccine.
1991: Launch of Bolheal – the first Japanese fibrin sealant
2001: Succeeded in full-length cDNA cloning of ADAMTS13
2014: Launch of a new haemostatic treatment for haemophillia patients with inhibitors: Byclot – human coagulation factor VIIa containing factor X
2018: Kaketsuken joined Meiji Group and renamed to KM Biologics.
2023: Approval of Quintovac, a pentavalent vaccine for use in Japan.
Key Products or Services:
Seasonal and pandemic influenza vaccines, Pentavalent vaccine, Japanese encephalitis vaccine, Human coagulation factors, Newborn Screening
Factory Equipment:
Dedicated facilities and equipment for manufacturing various types of vaccines and plasma derived therapies regularly inspected and approved by the Japanese authorities (PMDA).
Technology / R&D activities:
With a commitment to discovery, innovation, and excellence, our scientists carry out cutting-edge research that helps contribute to a healthy future for people around the world.
Inactivated COVID-19 vaccine
Live attenuated tetravalent dengue vaccine
Hexavalent vaccine
Recombinant vaccines
International Operations:
So far KM Biologics has supplied vaccines only in Japan. We are looking for strategic partners to explore the overseas markets.
Business Achievements:
After the 2009 pandemic influenza outbreak, we were the first in the world to establish a domestic vaccine supply system – and today we boast the capability to supply the vaccine to around 57 million people
Awards:
KM Biologics has been included in the list of “Certified Health & Productivity Management Outstanding Organizations Recognition Program” by the Ministry of Economy, Trade and Industry three consecutive years, as a company that has an excellent health and productivity management system in place.
Company Goals & Objectives:
Overseas expansion of registered products and testing systems.
Further broadening of our product portfolio with a focus on immunologic, hematologic and congenital disease area.
Becoming a strategic development, manufacturing and sales partner mainly in Japan and APAC region.
Developing new generation of pharmaceuticals by adoption of new modalities
